Rigel says it's nearing psoriasis pact

Fresh on the heels of a newly-announced $1.24 billion pact on a rheumatoid arthritis drug, Rigel Pharmaceuticals says it's nearing another deal on its psoriasis program. "We are continuing to work on R348 as a topical agent for psoriasis. It is likely that in the next three months we will announce a deal on R348," Chief Operating Officer Raul Rodriguez told Reuters. Rigel is looking to team up with a company with a sharp dermatological or ophthalmic focus before taking the therapy into a mid-stage trial. Report

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.